In This Section
Past Recipients CIC Walter Wolf Young Investigator Award
2021:
Mohammad Naghavi-Behzad, MD, MPH
“Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT”
2020:
Abhishek Jha, MBBS
"Superiority of68Ga-DOTATATE PET/CT compared to18F-FDG PET/CT and MRI of the spine in the detection of spinal bone metastases in metastatic pheochromocytoma and/or paraganglioma"
2019:
Jeremie Calais, MD
"68GA-PSMA-11 PET/CT detects prostate cancer at early biochemical recurrence with superior detection rate and reader agreement when compared to 18F-Fluciclovine PET/CT in a prospective head to head comparative phase 3 study"
2018:
Sungwook Jung, PhD
“Natural Killer cell labeled by gold-coated iron oxide nanoparticles: PET/MRI/PA monitoring and immuno-photothermal cancer therapy"
2017:
Raiyan Tripti Zaman, PhD
“Harnessing Radioluminescence and Sound to Reveal Molecular Pathology of Atherosclerotic Plaques"
2016:
Yong-il Kim
“Prognostic Value of Pre-treatment Ga-68-RGD PET-CT in Predicting Disease Free Survival in Patients with Breast Cancer: A Comparison Study with Dynamic Contrast Enhanced MRI.”
2015:
Chrystalla Loutsios
"SPECT/CT to quantify eosinophil migration into the lungs"
2014:
Jean-François Montégiani
Personalized 177 Lu-octreotate PPRT: cycle-to-cycle renal radiation dose prediction using quantitative SPECT/CT dosimetry
2013:
Matthias Eiber, MD, PhD
“Initial experience in restaging of patients with recurrent prostate cancer: Comparison of 11C-Choline-PET/MR and 11C-Choline-PET/CT”
2012:
Hai Jeon Yoon, MD
"Predicting histologic biomarker expression in breast cancer with 68Ga-RGD PET/CT versus diffusion-weighted and dynamic contrast-enhanced MRI"
2011:
Masahiro Yanagawa, MD, PhD
"Comparison of PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) in neoadjuvant chemotherapy for esophageal cancer"
2010:
Andrew Quon, MD
“Correlation between MRI and NaF PET/CT in patients with patellofemoral knee pain”
2009:
Patrick Veit-Haibach, MD
“Impact of F18-DOPA PET/CT on therapeutic management in patients neuroendocrine tumors”
2008:
Donna J. Cross, PhD
“Olfactory tract dysintegrity and cortical metabolic change in aging and MCI.”
2007:
Jan Soyka, MD
"Staging Pathways in Recurrent Colorectal Carcinoma. Is Contrast-enhanced 18-FDG-PET-CT the Diagnostic Tool of Choice?"